You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Mass. Movers

Biogen Idec jumps on Techfidera approval

Moody’s Investors Service also raised Biogen Idec’s ratings outlook to positive.

Suzanne Kreiter/Globe Staff/File

Moody’s Investors Service also raised Biogen Idec’s ratings outlook to positive.

Continue reading below

It was a good week for Biogen Idec Inc. shares after US regulators OK’d its first pill to treat multiple sclerosis, cementing the Weston company’s dominance in MS treatments. The FDA approved Tecfidera as a “first-line” treatment, meaning doctors can prescribe it for newly diagnosed patients and those already taking MS drugs. Analysts say Tecfidera potentially could become one of the top-selling prescription drugs of all time by the end of the decade.

Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.